Non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma, is predominantly driven by mutations in driver genes, primarily including anaplastic lymphoma kinase (ALK) rearrangements and epidermal growth factor receptor (EGFR) mutations (1). The gene discussed is EGFR; the disease is lung adenocarcinoma.